| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHGA |
| Uniprot No | P10645 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-457aa |
| 氨基酸序列 | MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGSHMLP VNSPMNKGDT EVMKCIVEVI SDTLSKPSPM PVSQECFETL RGDERILSIL RHQNLLKELQ DLALQGAKER AHQQKKHSGF EDELSEVLEN QSSQAELKEA VEEPSSKDVM EKREDSKEAE KSGEATDGAR PQALPEPMQE SKAEGNNQAP GEEEEEEEEA TNTHPPASLP SQKYPGPQAE GDSEGLSQGL VDREKGLSAE PGWQAKREEE EEEEEEAEAG EEAVPEEEGP TVVLNPHPSL GYKEIRKGES RSEALAVDGA GKPGAEEAQD PEGKGEQEHS QQKEEEEEMA VVPQGLFRGG KSGELEQEEE RLSKEWEDSK RWSKMDQLAK ELTAEKRLEG QEEEEDNRDS SMKLSFRARA YGFRGPGPQL RRGWRPSSRE DSLEAGLPLQ VRGYPEEKKE EEGSANRRPE DQELESLSAI EAELEKVAHQ LQALRRG |
| 预测分子量 | 51 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHGA(嗜铬粒蛋白A)重组蛋白的3篇参考文献的简要列举：
1. **文献名称**：*Recombinant human chromogranin A: purification and characterization of a naturally occurring novel vascular paracrine modulator*
**作者**：Angela M. Hendy et al.
**摘要**：该研究成功表达并纯化了重组人源CHGA蛋白，揭示了其调节血管内皮功能的活性，提示其在心血管疾病中的潜在调控作用。
2. **文献名称**：*Production and characterization of monoclonal antibodies against human chromogranin A*
**作者**：Laurence Taupenot et al.
**摘要**：利用重组CHGA蛋白制备单克隆抗体，验证了抗体在神经内分泌肿瘤诊断中的高特异性，为临床检测提供新工具。
3. **文献名称**：*Chromogranin A: a novel regulator of catecholamine storage and release*
**作者**：Sushil K. Mahata et al.
**摘要**：通过重组蛋白实验，阐明了CHGA在调控儿茶酚胺储存与分泌中的分子机制，强调了其在神经内分泌信号传递中的关键角色。
这些研究覆盖了CHGA重组蛋白的制备、功能分析及临床应用，反映了其多学科研究价值。
Chromogranin A (CHGA), a member of the granin family of acidic secretory proteins, is a key component of neuroendocrine secretory granules. It is ubiquitously expressed in neurons, endocrine cells, and neuroendocrine tumors, where it co-stores and co-releases with hormones, neuropeptides, and neurotransmitters. CHGA serves multiple roles: it regulates the biogenesis and stability of secretory granules through its calcium-binding capacity, modulates hormone processing by acting as a prohormone, and exhibits bioactive peptide fragments with diverse physiological functions. These fragments, including vasostatin, pancreastatin, and catestatin, influence cardiovascular homeostasis, glucose metabolism, immune responses, and antimicrobial activity.
Recombinant CHGA proteins are engineered to study its structure-function relationships and therapeutic potential. Produced via heterologous expression systems (e.g., E. coli, mammalian cells), they retain post-translational modifications critical for bioactivity. Recombinant CHGA enables researchers to investigate its role in neuroendocrine disorders, such as hypertension, heart failure, and neuroendocrine tumors, where CHGA levels serve as diagnostic biomarkers. Additionally, it aids in exploring its involvement in neurodegenerative diseases like Alzheimer’s and Parkinson’s, linked to dysregulated secretory pathways.
The development of recombinant CHGA has advanced drug discovery, particularly for cardiovascular and metabolic diseases. For example, catestatin derivatives are being explored as antihypertensive agents. However, challenges remain in mimicking native protein folding and post-translational modifications. Ongoing research focuses on optimizing expression systems and engineering bioactive peptides to harness CHGA’s therapeutic potential while addressing its dual role in both physiological regulation and disease pathogenesis.
×
